Healthcare / Drug Manufacturers - Specialty & GenericKSE
$9990.00
-210.00 (-2.06%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-17.5B · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$183.2B
P/E
N/A
•EV/EBITDA
19.3x
↑ROE
-13.5%
↓Gross Margin
26.2%
↓Debt/Equity
0.98
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.8%
FCF CAGR
—
FCF margin
-4.4%
FCF / Net income
0.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $145.93B · net income $-29.63B · FCF $-6.46B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $145.93B | $145.93B | $148.30B | $151.07B | $154.04B |
| Net Income | $-29.63B | $-29.63B | $4.15B | $3.58B | $7.43B |
| EBITDA | $20.39B | $20.39B | $12.76B | $9.01B | $11.55B |
| EPS | -1616.00 | -1616.00 | 226.00 | 195.00 | 407.00 |
| Gross Margin | 26.2% | 26.2% | 49.1% | 52.2% | 53.1% |
| Operating Margin | -21.0% | -21.0% | -0.4% | 2.0% | 6.1% |
| Net Margin | -20.3% | -20.3% | 2.8% | 2.4% | 4.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.98 | 0.98 | 0.82 | 0.91 | 0.85 |
| Current Ratio | 6.12 | 6.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.46B | $-6.46B | $-17.46B | $-20.23B | $-54.40B |
| Returns | |||||
| ROE | -13.5% | -13.5% | 1.7% | 1.4% | 3.0% |
| Valuation | |||||
| P/E | — | — | 59.12 | 84.67 | 49.63 |
| EV/EBITDA | 19.26 | 19.26 | 34.42 | 55.98 | 48.75 |
| P/B | 0.83 | 0.83 | 0.98 | 1.22 | 1.49 |
| Growth & Yield | |||||
| Revenue Growth | -1.6% | -1.6% | -1.8% | -1.9% | — |
| EPS Growth | -815.0% | -815.0% | 15.9% | -52.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.9%
Start / end P/E
n/dx → n/dx
EPS bridge
226.00 → -1616.00
Residual
-4.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.